Skyline Therapeutics developed SKG0106, a novel intravitreally delivered AAV gene therapy targeting neovascular age-related macular degeneration (nAMD).
SKG0106 is a distinctively designed recombinant adeno-associated virus (rAAV)-mediated gene therapy for ocular diseases. The therapy includes a proprietary novel AAV capsid, which is the outer shell of the virus, and a uniquely configured transgene genome that encodes the production of an anti-VEGF (vascular endothelial growth factor) protein.
SKG0106 is an investigational gene therapy utilising a proprietary novel recombinant adeno-associated viral vector. The therapy aims to prevent choroidal or retinal neovascularization, relieve retinal oedema, and reduce vascular leakage in patients with nAMD.
The therapy contains a uniquely configured transgene that has shown potent inhibition effects on intraocular neovascularization, making it a promising candidate for the treatment of serious ophthalmic conditions, including neovascular age-related macular degeneration (nAMD).
SKG0106 has undergone robust preclinical proof-of-concept studies, demonstrating its safety and efficacy as an anti-angiogenic treatment with durable suppression of neovascular lesions following a low-dose single intravitreal injection.
Skyline Therapeutics obtained FDA clearance of the Investigational New Drug (IND) application for SKG0106, a novel intravitreally delivered adeno-associated virus (AAV) gene therapy candidate.
